Humana to back curbs to Medicare Advantage billing practices, WSJ reports

Humana is reportedly supporting congressional efforts to limit Medicare Advantage billing practices that generate billions in extra payments for insurers, specifically related to diagnoses recorded by nurse practitioners during in-home visits. This move comes after scrutiny of the industry's practices, including a Justice Department examination of UnitedHealth's diagnosis recording, and as senators seek legislative solutions to address potential misuse of home visits for inflated payments. The change in stance by Humana could signal a broader shift in the industry's approach to Medicare Advantage billing amid increasing regulatory pressure.

Analysis

Humana Inc. (HUM) has reportedly indicated to congressional staffers its support for new legislative limits on certain Medicare Advantage billing practices, specifically targeting lucrative payments derived from diagnoses recorded by nurse practitioners during in-home visits. This development, detailed in a one-page policy overview, surfaces amidst heightened scrutiny of such practices within the industry, which are estimated to be worth billions in extra payments. The context includes U.S. Department of Justice (DOJ) examination of UnitedHealth Group's (UNH) diagnosis recording methods and ongoing efforts by Senate Finance Committee leaders to address potential misuse of home visits for inflating payments, as previously reported by the Wall Street Journal. With nearly half of the 65 million Medicare beneficiaries enrolled in private Medicare Advantage plans, where insurers receive higher payments for patients with multiple health conditions, Humana's stance could signal a preemptive move to navigate increasing regulatory pressure and potentially influence forthcoming legislation. This proactive approach by a major insurer like Humana may foreshadow broader changes in how Medicare Advantage plans are compensated, potentially impacting profitability across the sector.

Key Decisions for Investors

• Investors in Humana (HUM) should closely monitor legislative developments regarding Medicare Advantage billing practices, as new limits could impact future revenues despite the company's potentially favorable positioning by supporting changes.
• Holders of UnitedHealth (UNH) and other Medicare Advantage plan providers should factor in the heightened regulatory risk and the potential for margin compression if restrictions on current billing methodologies are broadly implemented, especially given the ongoing DOJ examination of UNH.
• Consider the moderately negative sentiment and potential for increased regulatory headwinds across the Medicare Advantage sector, which could reshape profitability models and growth expectations for companies heavily reliant on these plans.